Pulmonary Vascular Disease News

The American Thoracic Society International Conference will be held May 19 to 24 in Washington, D.C., with a broad focus on advocacy and global health in many different forms.

Temple University announced that a endovascular catheter, invented at its Lewis Katz School of Medicine and developed by Thrombolex, has been approved by the FDA for treatment of acute pulmonary embolism.

Data from a systematic review suggest that adults with isolated pulmonary embolism, the majority of whom are women, are more likely to have prevalent CVD and are at increased risk for arterial thrombosis.

World Pulmonary Hypertension Day is May 5 and is recognized among global organizations and groups to raise awareness about pulmonary hypertension and honor those living with this often-misdiagnosed disease.

Patients with pulmonary arterial hypertension associated with connective tissue disease demonstrate a “poor” 10-year rate of 59.9%, according to data published in Rheumatology.

Patients diagnosed with systemic sclerosis-related pulmonary hypertension in the last 10 years had better survival than those diagnosed prior, according to results published in American Journal of Respiratory and Critical Care Medicine.

For patients with chronic thromboembolic pulmonary hypertension, balloon pulmonary angioplasty was associated with an improvement in pulmonary hemodynamic parameters and quality of life measures, data from a single-center study show.

Patients with gout demonstrate an increased risk for venous thromboembolism during the 30 days following a flare consultation or hospitalization, according to data published in Arthritis & Rheumatology.

Among patients with pulmonary embolism who underwent percutaneous thrombectomy, women experienced more procedure complications and mortality than men, according to study results published in CHEST.

Techdow USA announced the FDA approval of its generic enoxaparin sodium for marketing in the U.S.